Intrexon | XON - Betriebsaufwand





Betriebsaufwand Veränderung Datum
Agenus USD -199.08M 22.15M 2026-06
Alaunos Therapeutics USD 1.01M 175K 2026-03
Amgen USD 11.69B 6.9B 2026-06
Anika Therapeutics USD 137.28M 3.38M 2026-06
Arrowhead Research USD 245.35M 30.35M 2026-06
AstraZeneca USD 12.22B 4.04B 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Gilead Sciences USD 3.95B 19.57B 2026-06
GlaxoSmithKline GBP 5.8B 468M 2026-06
Heron Therapeutics USD 40.55M 1.46M 2025-12
Incyte USD 973.64M 4.65B 2026-06
Intrexon USD 61.56M 26.1M 2024-06
Karyopharm Therapeutics USD 61.83M 9.9M 2026-03
Ligand Pharmaceuticals USD 55.1M 20.75M 2026-06
MacroGenics USD 42.87M 21.68M 2026-06
MannKind USD 110.21M 690K 2026-06
Merck USD 15.77B 2.4B 2026-06
Novartis USD 10.2B 912M 2026-06
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Roche Holding CHF 18.9B 2.12B 2026-06
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Thermo Fisher Scientific USD 9.81B 716M 2026-06
Veracyte USD 126.36M 6.37M 2026-06
Xencor USD 87.82M 5.44M 2026-06